Back to News
Market Impact: 0.45

Cathie Wood’s ARK sells Teradyne stock, buys CoreWeave By Investing.com

TERCRWVOKLOWGSDASHVCYTSRTAKDK
Energy Markets & PricesGeopolitics & WarTechnology & InnovationMarket Technicals & FlowsInvestor Sentiment & PositioningHealthcare & BiotechCompany Fundamentals
Cathie Wood’s ARK sells Teradyne stock, buys CoreWeave By Investing.com

Brent briefly hit $115 after a reported threat to Iranian energy infrastructure, pushing oil higher and signaling near-term energy market volatility. ARK disclosed large ETF activity: sold 29,130 Teradyne (TER) shares for $8,611,119 and cut 42,818 Veracyte (VCYT) shares for $1,284,968, while adding 41,830 CoreWeave (CRWV) for $3,129,302, 37,422 Oklo (OKLO) for $1,879,707, and 20,674 GeneDx (WGS) for $1,180,278; smaller trades include 2,527 DoorDash (DASH) for $370,458 and 35,911 Kodiak AI (KDK) for $248,145. Monitor ARK flow-driven moves in the listed names for potential 1–3% stock impacts and watch energy contracts for continued volatility if geopolitical rhetoric escalates.

Analysis

Geopolitical-driven energy volatility is the marginal amplifier across multiple sectors: higher and more volatile fuel and power costs will show up in cloud GPU economics and last-mile logistics first, compressing training margins and delivery unit economics within weeks. For asset allocators, this raises the value of businesses with fixed-price contracted capacity or embedded price escalation clauses — and conversely penalizes spot-exposed operators and small data-centers that rely on diesel back-up. The semiconductor equipment cycle looks bifurcated over the next 3–12 months — near-term order weakness can be amplified by sentiment-driven selling in high-beta test-equipment names, but advanced-node and heterogeneous-integration testing demand should re-accelerate mid- to late-2026 as AI ASIC tape-outs convert to production. That creates a dispersion trade: high-mix test specialists and niche IPP suppliers earn margin tailwinds while broad-market tester vendors face inventory digestion. In healthcare and small-cap biotech, episodic ETF flows and option-levered positioning will remain the dominant price driver over quarters; companies with recurring diagnostic revenues and clearer payer economics are de-risked relative to platform/early-stage plays. Lastly, investor positioning is the active risk: concentrated thematic ETFs can both create short-term opportunities and exacerbate drawdowns when liquidity is thin — watch block trades and options OI for early signs of rotation.